UPS is expanding its specialty pharmaceutical offerings by establishing UPS Cold Chain Solutions, a comprehensive suite of cold chain technologies, best-in-class capabilities, and new and expanded global facilities providing complete, end-to-end temperature-controlled logistics.
“Our customers have been taking advantage of our cold chain capabilities for years, but the pandemic caused UPS to move even faster to enhance an integrated set of cold chain solutions to support the future of the pharmaceutical and medical device industry,” said Wes Wheeler, UPS healthcare president.
“UPS’s near-perfect, on-time delivery of the Covid-19 vaccine proves how effectively and efficiently our network handles biologically derived drugs, even at extreme temperatures.”
Chronic and life-threatening diseases, including cancers, respiratory, autoimmune and cardiovascular conditions, are the fastest growing disease categories in the world, creating a rapid acceleration in the development of biologically derived, temperature-controlled drugs and therapies.
According to the Biopharma Cold Chain Sourcebook, cold chain trends show 48 percent growth between 2018 and 2024 for drugs that require at least 2 to 8 degrees Celsius storage and shipping.
Additionally, the overall market for cold chain services (packaging, transportation and data services) is expected to significantly accelerate growth over the next three years, growing by 24 percent by 2024, after posting a 10 percent increase from 2019 to 2020.
“The future of the healthcare and specialty pharmaceutical industries will increasingly rely on robust cold chain networks to safely deliver temperature-controlled drugs and therapies to customers,” said Kate Gutmann, UPS chief sales and solutions officer and SVP, UPS Global Healthcare.
“The continued evolution of our cold chain offerings ensures UPS is ready for the future and can continue to provide long-term value for our healthcare customers.”
